PepTalk 2017
PepTalk 2017

Pipeline One Header

Cambridge Healthtech Institute’s Thirteenth Annual
Recombinant Protein Therapeutics
Fusion Proteins and Beyond
January 9-10, 2017 | Hilton San Diego Bayfront | San Diego, CA


By combining modular building blocks that can reach targets not accessible to antibodies, fusion protein therapeutics possess advantages over antibody-based therapies. Fusion proteins’ customizable functionality translate into lower patient dosing, reduced production costs, and improved product homogeneity. This Recombinant Protein Therapeutics conference explores the varying constructs and “designs” of fusion protein molecules, and discloses how these proteins are being engineered to form more efficacious therapeutics that offer specificity with enhanced stability and longer half-life. Experts present case studies from R&D through clinical data, and share the results they’ve achieved.

Preliminary Agenda


INNOVATING PROTEIN THERAPEUTICS


KEYNOTE PRESENTATION: Fusion Protein Strategies for Generation of Biobetters

William R. Strohl, Ph.D., Vice President and Head, BioTherapeutics, Janssen R&D, Pharmaceutical companies of Johnson & Johnson


Targeted Thorium Conjugates: Novel First-in-Class Alpha Pharmaceuticals

Jenny Karlsson, Ph.D., Head, TCR Biochemistry, Thorium Conjugate Research, Bayer AS


IFIGHTING CANCER

Bispecific TNFR-Superfamily Agonists for Tumor Localized Immune Modulation

Shane Olwill, Ph.D., Vice President, Development and Head, Immuno-Oncology, Pieris Pharmaceuticals, Inc.

Engineered Ligand and Receptor-Based Fusion Proteins as Next-Generation Cancer Therapeutics

Jennifer R. Cochran, Ph.D., Associate Professor, Bioengineering, Stanford University

Strategies for Improving Current Enzyme-Based Therapy of Acute Lymphoblastic Leukemia: Molecular Engineering and Directed Evolution of Human L-Asparaginases

Manfred Konrad, Ph.D., Research Director, Enzyme Biochemistry, Max Planck Institute for Biophysical Chemistry


INEXT-GENERATION ENGINEERING

Blocking IL-17A with Unparalleled Affinity Using an Engineered Affibody-Based Ligand Trap

Joachim Feldwisch, Ph.D., Director, Preclinical Development, Research, Affibody AB

FcRn-Mediated Intracellular Trafficking and Recycling of Albumin Fusion Protein Therapeutics

Anne Verhagen, Ph.D., Group Leader, Cellular Biochemistry, CSL Limited


IDESIGNING EFFICACIOUS PROTEIN THERAPEUTICS

Therapeutic Strategies Combining Specificities on the Outside and Inside of Cells

Stefan Dübel, Ph.D., Professor and Head, Biotechnology, Technische Universität Braunschweig

Effects of Protein Aggregates on Fc Receptor Binding of Fusion Protein and Antibody Therapeutics

Marina Feschenko, Ph.D., Senior Scientist, Analytical Development, Biogen




For questions about the meeting, please contact:

Mary Ruberry
Senior Conference Director
Cambridge Healthtech Institute
Phone: 781-972-5421
Email: mruberry@healthtech.com

For partnering & sponsorship information, please contact:

Companies A-K
Jason Gerardi
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5452
Fax: 781-972-5470
Email: jgerardi@healthtech.com

Companies L-Z
Carol Dinerstein
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5471
Fax: 781-972-5470
Email: dinerstein@healthtech.com